Argenx reports Vyvgart sales streak, bolstered by launch in rare neuro disorder
Argenx’s Vyvgart has beat sales expectations for the eleventh quarter in a row, supported by strong uptake of a subcutaneous version of the drug in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
